This company is no longer active
Immune Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | n/a |
| Return on equity | n/a |
| Net Margin | n/a |
| Last Earnings Update | 30 Sep 2018 |
Recent past performance updates
No updates
Recent updates
No updates
Revenue & Expenses BreakdownBeta
How Immune Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 15 | 0 | -23 | 8 | 5 |
| 30 Jun 15 | 0 | -26 | 10 | 7 |
| 31 Mar 15 | 0 | -25 | 10 | 6 |
| 31 Dec 14 | 0 | -24 | 11 | 6 |
| 30 Sep 14 | 0 | -21 | 11 | 5 |
| 30 Jun 14 | 0 | -8 | 8 | 3 |
| 31 Mar 14 | 0 | -9 | 7 | 3 |
| 31 Dec 13 | 0 | -7 | 5 | 4 |
| 30 Sep 13 | 0 | -6 | 5 | 3 |
Quality Earnings: Insufficient data to determine if IMNP.Q has high quality earnings.
Growing Profit Margin: Insufficient data to determine if IMNP.Q's profit margins have improved over the past year.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if IMNP.Q's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Insufficient data to compare IMNP.Q's past year earnings growth to its 5-year average.
Earnings vs Industry: Insufficient data to determine if IMNP.Q's earnings growth over the past year exceeded the Biotechs industry average.
Return on Equity
High ROE: IMNP.Q has a negative Return on Equity (0%), as it is currently unprofitable.